PT1853285E - Método para tratamento de inflamação associada a depósitos de amilóide e inflamação cerebral envolvendo microglia activada - Google Patents

Método para tratamento de inflamação associada a depósitos de amilóide e inflamação cerebral envolvendo microglia activada Download PDF

Info

Publication number
PT1853285E
PT1853285E PT06734085T PT06734085T PT1853285E PT 1853285 E PT1853285 E PT 1853285E PT 06734085 T PT06734085 T PT 06734085T PT 06734085 T PT06734085 T PT 06734085T PT 1853285 E PT1853285 E PT 1853285E
Authority
PT
Portugal
Prior art keywords
amyloid deposits
activated microglia
involving activated
brain
inflammation associated
Prior art date
Application number
PT06734085T
Other languages
English (en)
Inventor
Beka Solomon
Orna Goren
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of PT1853285E publication Critical patent/PT1853285E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PT06734085T 2005-02-01 2006-01-31 Método para tratamento de inflamação associada a depósitos de amilóide e inflamação cerebral envolvendo microglia activada PT1853285E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64838305P 2005-02-01 2005-02-01

Publications (1)

Publication Number Publication Date
PT1853285E true PT1853285E (pt) 2011-06-06

Family

ID=36589064

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06734085T PT1853285E (pt) 2005-02-01 2006-01-31 Método para tratamento de inflamação associada a depósitos de amilóide e inflamação cerebral envolvendo microglia activada

Country Status (14)

Country Link
US (3) US7867487B2 (pt)
EP (1) EP1853285B1 (pt)
JP (1) JP5096169B2 (pt)
CN (1) CN101166536B (pt)
AT (1) ATE501723T1 (pt)
CY (1) CY1111455T1 (pt)
DE (1) DE602006020697D1 (pt)
DK (1) DK1853285T3 (pt)
ES (1) ES2363203T3 (pt)
HK (1) HK1110790A1 (pt)
PL (1) PL1853285T3 (pt)
PT (1) PT1853285E (pt)
SI (1) SI1853285T1 (pt)
WO (1) WO2006083795A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE541038T1 (de) * 2006-07-21 2012-01-15 Univ Ramot Verwendung eines phagen mit anzeige eines peptids eines adhäsionsproteins zur behandlung einer erkrankung im zusammenhang mit intrazellulärer bildung von fibrillären proteineinschlüssen oder aggregraten
US20110182948A1 (en) 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque
JP2012509672A (ja) * 2008-11-24 2012-04-26 ラモト アト テル−アヴィヴ ユニバーシティ リミテッド 繊維状バクテリオファージを使用してパーキンソン病を処置するための方法
EP2683391B1 (en) 2011-03-11 2015-05-06 Ramot at Tel Aviv University, Ltd. Filamentous bacteriophage for use in the treatment of neurodegenerative tauopathy
EP2736522A1 (en) * 2011-07-27 2014-06-04 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
US20130084337A1 (en) * 2011-08-05 2013-04-04 Neurophage Pharmaceuticals, Inc. Pure filamentous bacteriophage and methods of producing same
JP6220344B2 (ja) 2011-11-29 2017-10-25 プロクララ バイオサイエンシーズ， インコーポレイテッド アミロイド結合剤としてのバクテリオファージのｐ３の使用
EP2825201A4 (en) * 2012-03-15 2015-12-09 Univ Ramot FILAMENTOUS BACTERIOPHAGE AS A MODULATOR OF ANGIOGENESIS
US9655933B2 (en) 2012-03-15 2017-05-23 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage as an angiogenesis modulator
KR102101258B1 (ko) 2012-10-02 2020-04-16 프로클라라 바이오사이언시즈, 인크. 아밀로이드 결합 물질로서 박테리오파지 융합 단백질의 p3의 용도
US9988444B2 (en) * 2013-05-28 2018-06-05 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
JP6730988B2 (ja) 2014-12-03 2020-07-29 プロクララ バイオサイエンシーズ， インコーポレイテッド グリコシル化シグナルを欠く改変バクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509020A (ja) * 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
AU2003205623A1 (en) 2002-01-18 2003-07-30 Cytos Biotechnology Ag Prion protein carrier-conjugates

Also Published As

Publication number Publication date
CN101166536B (zh) 2012-06-27
ES2363203T3 (es) 2011-07-26
WO2006083795A1 (en) 2006-08-10
CY1111455T1 (el) 2015-08-05
EP1853285A2 (en) 2007-11-14
JP2008528688A (ja) 2008-07-31
CN101166536A (zh) 2008-04-23
PL1853285T3 (pl) 2011-08-31
DK1853285T3 (da) 2011-06-27
US20090180991A1 (en) 2009-07-16
US7867487B2 (en) 2011-01-11
WO2006083795A8 (en) 2007-03-15
HK1110790A1 (en) 2008-07-25
US20110142803A1 (en) 2011-06-16
SI1853285T1 (sl) 2011-07-29
JP5096169B2 (ja) 2012-12-12
US20130177533A1 (en) 2013-07-11
EP1853285B1 (en) 2011-03-16
ATE501723T1 (de) 2011-04-15
US8361458B2 (en) 2013-01-29
DE602006020697D1 (de) 2011-04-28

Similar Documents

Publication Publication Date Title
HK1110790A1 (en) Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
TW200635608A (en) Aβ antibodies for use in improving cognition
TW200635607A (en) Humanized Aβ antibodies for use in improving cognition
WO2007084181A3 (en) Bispecific single chain fv antibody molecules and methods of use thereof
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
MX2008012023A (es) Metodos para prevenir y tratar enfermedades amiloidogenicas.
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
MY149630A (en) Antibodies against amyloid-beta peptide
WO2007115045A3 (en) Diagnostics and treatments for tumors
TW200728466A (en) Antibody molecules having specificity for human IL-6
BRPI0512500A (pt) tratamento ou condições envolvendo desmielinação
WO2006057997A3 (en) Plasmin-inhibitory therapies
TW200507840A (en) Method of treating multiple myeloma
WO2005099755A3 (en) Methods of treating autoimmune and inflammatory diseases
GB2475660A (en) Methods and kits for treating cluster headache disorders
MX2009009693A (es) Metodos para activar irs-1 y akt.
WO2006122035A3 (en) Method for treating central pain syndrome or for inducing centrally generated pain in an animal model
AR059209A1 (es) Un metodo para tratar una mezcla de aldehido, el uso del aldehido tratado, y un alcohol
WO2008033368A3 (en) Boroproline compound and cytokine combination therapy
WO2007058957A3 (en) Boroproline compound and cytokine combination therapy
WO2004105698A3 (en) Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders